NCT01836705View on ClinicalTrials.gov

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

May 31, 2014

Conditions
Neoplasm Malignant
Interventions
DRUG

SAR302503 (TG101348)

"Pharmaceutical form:capsule~Route of administration: oral"

DRUG

Placebo SAR302503

"Pharmaceutical form:capsule~Route of administration: oral"

DRUG

Panolosetron

"Pharmaceutical form:solution~Route of administration: intravenous"

Trial Locations (10)

1200

Investigational Site Number 056001, Brussels

9000

Investigational Site Number 056002, Ghent

19111

Investigational Site Number 840005, Philadelphia

30912

Investigational Site Number 840007, Augusta

48201

Investigational Site Number 840002, Detroit

63110

Investigational Site Number 840001, St Louis

78229

Investigational Site Number 840006, San Antonio

Investigational Site Number 840008, San Antonio

90048

Investigational Site Number 840003, Los Angeles

45267-0542

Investigational Site Number 840004, Cincinnati

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY